Hair Loss Prevention Study for Pancreatic Cancer

Inclusion Criteria: * Willing and able to provide written informed consent/assent for the trial * \>18 years of age on day of signing informed consent * Diagnosis of pancreatic cancer and scheduled to receive treatment with a regimen containing nab-paclitaxel, gemcitabine and cisplatin Exclusion Criteria: * Grade 1 alopecia * Existing history of scalp metastases or the presence of scalp metastases is suspected * No history of previous cancers within the past 5 years * CNS malignancies (either primary or metastatic) * Cold sensitivity, cold agglutinin disease, cryoglobulinemia, cryofibrinogenemia, cold migraine, cold urticaria, post-traumatic cold dystrophy * Imminent bone marrow ablation chemotherapy * Imminent skull radiation * Previously received or scheduled to undergo skull irradiation * Severe liver or renal disease from any etiology as patient may not be able to metabolize or clear the metabolites of the chemotherapeutic agent * Skin cancers including melanoma, squamous cell carcinoma and Merkel cell carcinoma * Small cell carcinoma of the lung * Solid tumors that have a high likelihood for metastasis in transit * Squamous cell carcinoma of the lung